Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

The Department of Health Services has awarded $590 million to Moderna to speed up the development of flu vaccines, including ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Another study found that in late 2021 and 2022, COVID death rates among unvaccinated people were 14 times the rates of those ...

Here the authors analyze data from COVAIL trial participants receiving an mRNA second COVID-19 vaccine boost and show that, while neutralizing antibody titer is correlated with Omicron COVID-19 ...